Mumbai, Jan. 27 -- Wockhardt announced that its novel intravenous antibiotic Foviscu(R) (WCK 4282) has successfully met the primary endpoint in a Phase 3 clinical trial in patients with complicated urinary tract infections (cUTI) and acute pyelonephritis caused by Gram-negative bacteria, including extended-spectrum a-lactamase (ESBL) producing pathogens. ESBL enzymes make many commonly used antibiotics ineffective and are a major cause of difficult-to-treat hospital infections.

Published by HT Digital Content Services with permission from Capital Market....